NCT05190575View on ClinicalTrials.gov

TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 14, 2022

Primary Completion Date

May 6, 2023

Study Completion Date

May 6, 2023

Conditions
Biliary Tract Neoplasms
Interventions
DRUG

TST001

TST001 IV infusion every 3 weeks until disease progression or other discontinuation criteria.

Trial Locations (1)

200032

Zhongshan hospital, Shanghai

All Listed Sponsors
collaborator

Transcenta Holding Limited

UNKNOWN

lead

Shanghai Zhongshan Hospital

OTHER